Skip to main content

Length of Stay After Lung Cancer Surgery Longer With Wildfire in County of Treating Facility

Medically reviewed by Carmen Pope, BPharm. Last updated on March 14, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, March 14, 2025 -- Patients with non-small cell lung cancer undergoing lobectomy or pneumonectomy whose treatment facility was in a U.S. county impacted by a wildfire disaster during recovery had a longer length of stay (LOS), according to a study published online March 11 in the Journal of the National Cancer Institute.

Leticia M. Nogueira, Ph.D., M.P.H., from the American Cancer Society in Atlanta, and colleagues selected individuals aged 18 years and older who received curative-intent lobectomy or pneumonectomy for stage I to III non-small cell lung cancer between 2004 and 2021. Differences in the cumulative distribution function of LOS were assessed between those exposed to a Federal Emergency Management Agency wildfire Presidential Disaster Declaration in the county of the treating facility between date of surgery and date of discharge from the hospital and propensity score-matched unexposed patients treated at the same facility (535 and 535 patients).

The researchers found that exposed patients had significantly longer LOS than unexposed patients (9.4 versus 7.5 days) overall and for each stage (I to III) for which surgery is the recommended modality of treatment.

"These findings underscore the importance of developing specific disaster preparedness and response guidelines for specific patient populations and incorporating contextual factors in health care quality measures tied to clinician and facility payments, such as shorter LOS," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted March 2025

Read this next

American Society of Clinical Oncology, May 31-June 3

The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more than 35,000 participants, including clinicians...

ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer

THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...

Endolymphatic Sac Decompression Effective for Vertigo, Migraine

WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.